Pluri Inc. (PLUR) |
|
1.15 -0.04 (-3.36%)
|
01-27 15:57 |
|
Open: |
1.2 |
Pre. Close: |
1.19 |
|
High:
|
1.2 |
Low:
|
1.145 |
|
Volume:
|
22,086 |
Market Cap:
|
45(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:08 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.44 One year: 1.69 |
| Support: |
Support1: 0.89 Support2: 0.74 |
| Resistance: |
Resistance1: 1.23 Resistance2: 1.44 |
| Pivot: |
1.16  |
| Moving Average: |
MA(5): 1.18 MA(20): 1.11
MA(100): 0.87 MA(250): 1.24 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 40.1 %D(3): 44.6 |
| RSI: |
RSI(14): 54.9 |
| 52-week: |
High: 2.21 Low: 0.64 |
| Average Vol(K): |
3-Month: 81 (K) 10-Days: 81 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLUR ] has closed above bottom band by 46.6%. Bollinger Bands are 54.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.2 - 1.21 |
1.21 - 1.21 |
|
Low:
|
1.13 - 1.14 |
1.14 - 1.14 |
|
Close:
|
1.14 - 1.15 |
1.15 - 1.16 |
|
Company Description |
|
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. |
Headline News |
Fri, 27 Jan 2023
TSX Venture Exchange Stock Maintenance Bulletins - Investing News Network
Fri, 27 Jan 2023
Photo gallery: 'Sailor Moon' fans bring the superhero to a rave in ... - Mashable
Fri, 27 Jan 2023
Plurilock Security (PLUR.V) builds a safe workplace without ... - Equity.Guru
Mon, 23 Jan 2023
Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak - Seeking Alpha
Tue, 17 Jan 2023
Remarks by President Biden and Vice President Harris Honoring the ... - The White House
Mon, 16 Jan 2023
Plurilock Security (PLUR.V) releases application powered by ChatGPT - Equity.Guru
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
2.777e+007 (%) |
|
% Held by Institutions
|
7.5 (%) |
|
Shares Short
|
165 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.054e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-17 |
|
Return on Assets (ttm)
|
774.7 |
|
Return on Equity (ttm)
|
-32.2 |
|
Qtrly Rev. Growth
|
234000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-52.93 |
|
EBITDA (p.s.)
|
133714 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-37 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.03 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
143080 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
